Compare BNC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 262.5M |
| IPO Year | 2010 | 2014 |
| Metric | BNC | PRQR |
|---|---|---|
| Price | $3.28 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 180.8K | ★ 925.0K |
| Earning Date | 07-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.72 | N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $9,581,968.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $1.12 | ★ N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $1.84 | $1.33 |
| 52 Week High | $20.95 | $3.10 |
| Indicator | BNC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 52.36 |
| Support Level | $2.37 | $1.40 |
| Resistance Level | $4.14 | $2.25 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 80.05 | 38.60 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.